Corbion (AMS:CRBN) First Half 2024 Results
Key Financial Results
- Revenue: €637.1m (flat on 1H 2023).
- Net income: €22.7m (up 47% from 1H 2023).
- Profit margin: 3.6% (up from 2.4% in 1H 2023).
- EPS: €0.39 (up from €0.26 in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Corbion Earnings Insights
Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 4.7% growth forecast for the Chemicals industry in Europe.
Performance of the market in the Netherlands.
The company's shares are up 5.9% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 2 warning signs for Corbion you should be aware of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTAM:CRBN
Corbion
Provides lactic acid and lactic acid derivatives, other ferment, functional enzyme blends, minerals, vitamins, and algae ingredients worldwide.
Solid track record, good value and pays a dividend.
